{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:47:51Z","timestamp":1782762471291,"version":"3.54.5"},"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Although programmed cell death-ligand 1 (PD-L1) has been recognized as a potential marker in several cancers, the relationship between PD-L1 expression and survival in patients with salivary gland carcinoma (SGC) has remained unclear. We aimed to evaluate the association of PD-L1 expression with clinicopathological features and prognosis in SGC patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The databases Ovid Medline, PubMed, Scopus, and EMBASE were searched for relevant studies that detected PD-L1 expression in SGC. The meta-analysis was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA), and the reporting recommendations for tumor marker prognostic studies (REMARK) was used to assess the quality of research eligible for this meta-analysis. Included studies were assessed using the Quality in Prognosis Studies (QUIPS) tool. Odds ratios (ORs) with 95% confidence interval (CI) were calculated to estimate the correlation between PD-L1 expression and clinicopathological features. Hazard ratios (HRs) with 95% CI were applied to assess the association between PD-L1 expression and survival outcomes of patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of ten studies (including 952 patients with SGC) were evaluated. The meta-analysis showed that positive PD-L1 expression in SGC was significantly associated with male patients, older age, Tumor stage, lymph node metastasis, high pathological grade, and non-adenoid cystic carcinoma subtype. The pooled data demonstrated that high PD-L1 expression was associated with poor overall survival and disease-free survival. There was no significant correlation between PD-L1 expression and progression-free survival or disease-specific survival of SGC patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>According to the meta-analysis, positive PD-L1 expression may play an important role as an effective marker of poor prognosis in patients with SGC. However, large-scale, prospective investigations are still needed to confirm the findings. The assessment of PD-L1 expression may aid in the personalized management of SGC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0272080","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T17:54:59Z","timestamp":1658858099000},"page":"e0272080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9382-6447","authenticated-orcid":true,"given":"Limeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3687-8061","authenticated-orcid":true,"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"6","key":"pone.0272080.ref001","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0194-5998(99)70323-2","article-title":"Incidence rates of salivary gland tumors: results from a population-based study.","volume":"120","author":"JA Pinkston","year":"1999","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"11","key":"pone.0272080.ref002","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1055-9965.EPI-09-0638","article-title":"Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States","volume":"18","author":"H Boukheris","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"pone.0272080.ref003","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11912-012-0220-5","article-title":"Salivary gland cancers: biology and molecular targets for therapy","volume":"14","author":"D Bell","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"pone.0272080.ref004","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.canep.2014.07.014","article-title":"The burden of rare cancer in Japan: application of the RARECARE definition","volume":"38","author":"T Tamaki","year":"2014","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"pone.0272080.ref005","first-page":"169","article-title":"Management of clinically negative neck in salivary gland cancers\u2014elective neck dissection, irradiation, or surveillance?","volume":"23","author":"M Szewczyk","year":"2019","journal-title":"Contemp Oncol (Pozn)"},{"key":"pone.0272080.ref006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.oraloncology.2015.11.023","article-title":"Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy.","volume":"54","author":"A Hosni","year":"2016","journal-title":"Oral Oncol"},{"issue":"2","key":"pone.0272080.ref007","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.otc.2015.11.001","article-title":"Diagnosis and Management of Malignant Salivary Gland Tumors of the Parotid Gland.","volume":"49","author":"AG Lewis","year":"2016","journal-title":"Otolaryngol Clin North Am"},{"issue":"4","key":"pone.0272080.ref008","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/ssu.2980030405","article-title":"Carcinoma of the salivary gland: a clinicopathologic study of 405 cases.","volume":"3","author":"GY Yu","year":"1987","journal-title":"Semin Surg Oncol"},{"issue":"Suppl 1","key":"pone.0272080.ref009","doi-asserted-by":"crossref","first-page":"E820","DOI":"10.1002\/hed.24107","article-title":"Salivary duct carcinoma: Treatment, outcomes, and patterns of failure.","volume":"38","author":"ML Johnston","year":"2016","journal-title":"Head Neck"},{"key":"pone.0272080.ref010","article-title":"Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: Systematic review.","author":"O Guntinas-Lichius","year":"2020","journal-title":"Head Neck"},{"key":"pone.0272080.ref011","first-page":"2617","article-title":"The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis.","volume":"8","author":"B Huang","year":"2015","journal-title":"Onco Targets Ther."},{"issue":"9","key":"pone.0272080.ref012","first-page":"14595","article-title":"Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.","volume":"8","author":"F Xu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"pone.0272080.ref013","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s11523-016-0451-8","article-title":"Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.","volume":"11","author":"X Li","year":"2016","journal-title":"Target Oncol"},{"issue":"1","key":"pone.0272080.ref014","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/ol.2017.6105","article-title":"PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma.","volume":"14","author":"K Ma","year":"2017","journal-title":"Oncol Lett"},{"issue":"2","key":"pone.0272080.ref015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s10620-019-05787-0","article-title":"Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma","volume":"65","author":"Z Dong","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"1","key":"pone.0272080.ref016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24266","article-title":"Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas","volume":"114","author":"T Mukaigawa","year":"2016","journal-title":"Journal of surgical oncology"},{"issue":"1","key":"pone.0272080.ref017","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12885-018-4069-3","article-title":"PD-L1 expression in malignant salivary gland tumors","volume":"18","author":"K Harada","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"pone.0272080.ref018","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.1038\/s41598-019-49215-9","article-title":"The expression of PD-L1 in salivary gland carcinomas.","volume":"9","author":"D Vital","year":"2019","journal-title":"Scientific reports"},{"issue":"9","key":"pone.0272080.ref019","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1002\/hed.25857","article-title":"Prognostic markers in salivary gland cancer and their impact on survival","volume":"41","author":"M Szewczyk","year":"2019","journal-title":"Head Neck"},{"issue":"5","key":"pone.0272080.ref020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/his.13944","article-title":"The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma","volume":"75","author":"B Xu","year":"2019","journal-title":"Histopathology"},{"issue":"4","key":"pone.0272080.ref021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"D Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"pone.0272080.ref022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1741-7015-10-51","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.","volume":"10","author":"DG Altman","year":"2012","journal-title":"BMC Med"},{"key":"pone.0272080.ref023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"JF Tierney","year":"2007","journal-title":"Trials"},{"issue":"4","key":"pone.0272080.ref024","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"JA Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"pone.0272080.ref025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anndiagpath.2019.04.001","article-title":"PD-L1 expression by immunohistochemistry in salivary duct carcinoma.","volume":"40","author":"A Hamza","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"pone.0272080.ref026","doi-asserted-by":"crossref","first-page":"16988","DOI":"10.1038\/s41598-020-73965-6","article-title":"Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.","volume":"10","author":"K Niwa","year":"2020","journal-title":"Scientific reports"},{"issue":"5","key":"pone.0272080.ref027","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050965","article-title":"Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.","volume":"13","author":"S Hiss","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pone.0272080.ref028","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hed.26587","article-title":"The tumor immune contexture of salivary duct carcinoma.","volume":"43","author":"G Schvartsman","year":"2021","journal-title":"Head Neck"},{"issue":"8","key":"pone.0272080.ref029","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","article-title":"Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes","volume":"4","author":"V Sridharan","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"pone.0272080.ref030","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00066-017-1196-8","article-title":"Impact of postoperative radiotherapy and HER2\/new overexpression in salivary duct carcinoma: A monocentric clinicopathologic analysis.","volume":"193","author":"M Haderlein","year":"2017","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]."},{"key":"pone.0272080.ref031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.archoralbio.2017.07.004","article-title":"Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma","volume":"83","author":"C Mosconi","year":"2017","journal-title":"Arch Oral Biol"},{"issue":"17","key":"pone.0272080.ref032","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"SM Gargano","year":"2019","journal-title":"Cancer Med"},{"key":"pone.0272080.ref033","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.11.028","article-title":"Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.","volume":"88","author":"C Mosconi","year":"2019","journal-title":"Oral Oncol"},{"issue":"4","key":"pone.0272080.ref034","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s12105-020-01163-x","article-title":"Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.","volume":"14","author":"K Chatzopoulos","year":"2020","journal-title":"Head Neck Pathol"},{"issue":"8","key":"pone.0272080.ref035","doi-asserted-by":"crossref","first-page":"FSO616","DOI":"10.2144\/fsoa-2020-0063","article-title":"Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers.","volume":"6","author":"T Steiniche","year":"2020","journal-title":"Future Sci OA"},{"issue":"2","key":"pone.0272080.ref036","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020097","article-title":"The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1\/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay.","volume":"9","author":"M Kuchar","year":"2021","journal-title":"Biomedicines"},{"key":"pone.0272080.ref037","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2147\/OTT.S134589","article-title":"Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors.","volume":"10","author":"H Chang","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"1","key":"pone.0272080.ref038","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.25011\/cim.v44i1.35218","article-title":"Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland","volume":"44","author":"W Chen","year":"2021","journal-title":"Clin Invest Med"},{"key":"pone.0272080.ref039","doi-asserted-by":"crossref","first-page":"618367","DOI":"10.3389\/fimmu.2021.618367","article-title":"The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.","volume":"12","author":"S Dou","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0272080.ref040","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/jop.12722","article-title":"The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.","volume":"47","author":"F Sato","year":"2018","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"pone.0272080.ref041","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/00016489.2019.1683604","article-title":"Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma.","volume":"140","author":"M Higashino","year":"2020","journal-title":"Acta Otolaryngol"},{"key":"pone.0272080.ref042","doi-asserted-by":"crossref","first-page":"104931","DOI":"10.1016\/j.oraloncology.2020.104931","article-title":"Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer","volume":"111","author":"N Kesar","year":"2020","journal-title":"Oral Oncol"},{"issue":"3","key":"pone.0272080.ref043","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/hed.26529","article-title":"Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.","volume":"43","author":"E Guazzo","year":"2021","journal-title":"Head Neck"},{"issue":"5","key":"pone.0272080.ref044","doi-asserted-by":"crossref","first-page":"E1481","DOI":"10.1002\/lary.29120","article-title":"Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma","volume":"131","author":"F Sato","year":"2021","journal-title":"Laryngoscope"},{"key":"pone.0272080.ref045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.oraloncology.2019.01.015","article-title":"Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.","volume":"90","author":"T Nakano","year":"2019","journal-title":"Oral Oncol"},{"key":"pone.0272080.ref046","doi-asserted-by":"crossref","first-page":"701181","DOI":"10.3389\/fonc.2021.701181","article-title":"Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.","volume":"11","author":"Q Fang","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"pone.0272080.ref047","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040873","article-title":"Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.","volume":"12","author":"HM Witte","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"1","key":"pone.0272080.ref048","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"S Chen","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0272080.ref049","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"X Jiang","year":"2019","journal-title":"Mol Cancer"},{"issue":"11","key":"pone.0272080.ref050","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.","volume":"41","author":"RB Cohen","year":"2018","journal-title":"Am J Clin Oncol."},{"issue":"4","key":"pone.0272080.ref051","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer","volume":"26","author":"CP Rodriguez","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0272080.ref052","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s10147-020-01829-0","article-title":"Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.","volume":"26","author":"N Hanai","year":"2021","journal-title":"International journal of clinical oncology"},{"issue":"1","key":"pone.0272080.ref053","doi-asserted-by":"crossref","first-page":"152768","DOI":"10.1016\/j.prp.2019.152768","article-title":"The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis","volume":"216","author":"H Tang","year":"2020","journal-title":"Pathol Res Pract"},{"key":"pone.0272080.ref054","doi-asserted-by":"crossref","first-page":"104717","DOI":"10.1016\/j.archoralbio.2020.104717","article-title":"Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis","volume":"114","author":"J He","year":"2020","journal-title":"Arch Oral Biol"},{"issue":"12","key":"pone.0272080.ref055","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","article-title":"The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype","volume":"26","author":"M Linxweiler","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"pone.0272080.ref056","doi-asserted-by":"crossref","first-page":"e0216864","DOI":"10.1371\/journal.pone.0216864","article-title":"Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNgamma signaling in non-small cell lung cancer","volume":"14","author":"W Theelen","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0272080.ref057","first-page":"134","article-title":"A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. International journal of radiation oncology, biology","volume":"109","author":"U Mahmood","year":"2021","journal-title":"physics"},{"issue":"12","key":"pone.0272080.ref058","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/lary.24238","article-title":"Mucoepidermoid carcinoma of the parotid gland treated by surgery and postoperative radiation therapy: clinicopathologic correlates of outcome","volume":"123","author":"AM Chen","year":"2013","journal-title":"Laryngoscope"},{"issue":"9","key":"pone.0272080.ref059","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/hed.26735","article-title":"Mucoepidermoid carcinoma of the parotid gland: Twenty-year experience in treatment and outcomes.","volume":"43","author":"SA Chan","year":"2021","journal-title":"Head Neck"},{"issue":"18","key":"pone.0272080.ref060","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1002\/cncr.27408","article-title":"Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973\u20132007 Surveillance, Epidemiology, and End Results data","volume":"118","author":"CL Ellington","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"pone.0272080.ref061","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/lary.24231","article-title":"Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases","volume":"124","author":"NR Patel","year":"2014","journal-title":"Laryngoscope"},{"issue":"6","key":"pone.0272080.ref062","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.amjoto.2019.102279","article-title":"Carcinoma ex pleomorphic adenoma: A review of incidence, demographics, risk factors, and survival","volume":"40","author":"A Gupta","year":"2019","journal-title":"American journal of otolaryngology"},{"issue":"21","key":"pone.0272080.ref063","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.21037\/atm-20-1849","article-title":"A population-based competing risk survival analysis of patients with salivary duct carcinoma.","volume":"8","author":"J Ran","year":"2020","journal-title":"Ann Transl Med"},{"issue":"2","key":"pone.0272080.ref064","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000484411","article-title":"Survival Outcome of Intermediate-Grade Salivary Gland Carcinoma","volume":"94","author":"GC Park","year":"2018","journal-title":"Oncology"},{"issue":"2","key":"pone.0272080.ref065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.oooo.2016.03.007","article-title":"Adenoid cystic carcinoma of the head and neck: a single-institution\u2019s analysis of 45 consecutive cases over a 29-year period.","volume":"122","author":"I Luksic","year":"2016","journal-title":"Oral surgery, oral medicine, oral pathology and oral radiology."},{"issue":"6","key":"pone.0272080.ref066","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1245\/s10434-015-5082-2","article-title":"Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients","volume":"23","author":"K Otsuka","year":"2016","journal-title":"Annals of surgical oncology"},{"issue":"10","key":"pone.0272080.ref067","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1007\/s10147-020-01731-9","article-title":"The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan.","volume":"25","author":"D Kawakita","year":"2020","journal-title":"International journal of clinical oncology"},{"issue":"12","key":"pone.0272080.ref068","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/hed.24908","article-title":"Prognostic nomogram for disease-specific survival of carcinoma ex pleomorphic adenoma of the salivary gland.","volume":"39","author":"YH Hu","year":"2017","journal-title":"Head Neck"},{"issue":"6","key":"pone.0272080.ref069","doi-asserted-by":"crossref","first-page":"e0179536","DOI":"10.1371\/journal.pone.0179536","article-title":"Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.","volume":"12","author":"J Li","year":"2017","journal-title":"PLoS One"},{"key":"pone.0272080.ref070","doi-asserted-by":"crossref","first-page":"104722","DOI":"10.1016\/j.oraloncology.2020.104722","article-title":"Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis","volume":"106","author":"D Lenouvel","year":"2020","journal-title":"Oral Oncol"},{"key":"pone.0272080.ref071","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.oraloncology.2018.09.016","article-title":"The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis","volume":"86","author":"WF Yang","year":"2018","journal-title":"Oral Oncol"},{"issue":"4","key":"pone.0272080.ref072","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hed.26036","article-title":"Impact of PD-L1 expression and human papillomavirus status in anti-PD1\/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis","volume":"42","author":"JJ Patel","year":"2020","journal-title":"Head Neck"},{"issue":"2","key":"pone.0272080.ref073","doi-asserted-by":"crossref","first-page":"501","DOI":"10.18632\/aging.101756","article-title":"Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis","volume":"11","author":"YQ Jia","year":"2019","journal-title":"Aging (Albany NY)."},{"issue":"19","key":"pone.0272080.ref074","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"RL Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10212","key":"pone.0272080.ref075","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"B Burtness","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"pone.0272080.ref076","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41379-019-0383-9","article-title":"Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays\u2019 and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort","volume":"33","author":"E Thunnissen","year":"2020","journal-title":"Mod Pathol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T17:56:27Z","timestamp":1658858187000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272080"}},"subtitle":[],"editor":[{"given":"Andrew","family":"Birkeland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":76,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0272080","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]}}}